{"DataElement":{"publicId":"62693","version":"3","preferredName":"Neoadjuvant Therapy Prior Chemotherapy Administered Ind-3","preferredDefinition":"the yes/no indicator that asks whether the patient had chemotherapy as treatment for this cancer.","longName":"NEO_PR_CT_ADM_IND","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2737094","version":"1","preferredName":"Neoadjuvant Therapy Prior Chemotherapy Administered","preferredDefinition":"information related to the prior administration of neoadjuvant chemotherapy, synthetic or naturally-occurring chemicals for the treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents.","longName":"NEOTX_PRI_CT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2718486","version":"1","preferredName":"Neoadjuvant Therapy","preferredDefinition":"Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.","longName":"C15665","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D7D4EB-6EB9-0FF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"ONEDATA","dateModified":"2008-01-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2737092","version":"1","preferredName":"Prior Chemotherapy Administered","preferredDefinition":"Earlier in time or order.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04):Given.","longName":"C25629:C15632:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49588753-48A5-45D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-26","modifiedBy":"SBREXT","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49588753-48B6-45D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-03-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506034","version":"1","preferredName":"Yes No Unknown Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.","longName":"YES_NO_UNKNOWN_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"7","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D05-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D0F-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3241403","version":"1","preferredName":"Unknown","longName":"3241403","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A4499CFB-7A3A-DD4D-E040-BB89AD4307BF","latestVersionIndicator":"Yes","beginDate":"2011-05-27","endDate":null,"createdBy":"DWARZEL","dateCreated":"2011-05-27","modifiedBy":"MMADDINENI","dateModified":"2023-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C379D9D0-6D1A-CCDD-E040-BB89AD432590","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2548260","version":"1","preferredName":"Ind-3","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no/unknown.","longName":"C38148","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Unknown Response","conceptCode":"C38148","definition":"A response or indicator that can have a value of yes, no, or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"23801A33-5B13-534B-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2006-11-30","endDate":"2016-04-27","createdBy":"BIRNBAUA","dateCreated":"2006-11-30","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 4-27-2016 per Tina Taylor approved by Dianne Reeves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C379D9D0-6CF1-CCDD-E040-BB89AD432590","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TITARENI","dateModified":"2021-09-14","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 3/35/2016 jk removed \"indeterminate\" value that was added in error. 7/7/2021wz: added ALT VM name for HOPE-CARE project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"},{"publicId":"2811913","version":"1","longName":"Lymphoma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811953","version":"1","longName":"Disease Description","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000311","version":"1","longName":"Met/Urothelial","context":"CTEP"},{"publicId":"10000462","version":"1","longName":"Muscle Invasive Blad","context":"CTEP"},{"publicId":"2811943","version":"1","longName":"Hodgkin's Lymphoma","context":"CTEP"},{"publicId":"2811944","version":"1","longName":"NonHodgkins Lymphoma","context":"CTEP"}]},{"publicId":"5242953","version":"1","longName":"BCAN: Bladder Cancer Advocacy Network","context":"NCIP","ClassificationSchemeItems":[{"publicId":"5242975","version":"1","longName":"UC-GENOME","context":"NCIP"}]}],"AlternateNames":[{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"NEO_PR_CT_ADM_IND","type":"USED_BY","context":"CCTG"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"IE_IEORRES_PRIORTX","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Prior Neoadjuvant Chemotherapy Ind","url":null,"context":"CTEP"},{"name":"Prior Neoadjuvant Chemotherapy","type":"Preferred Question Text","description":"Prior Neoadjuvant Chemotherapy","url":null,"context":"CTEP"},{"name":"CRF Text 1","type":"Alternate Question Text","description":"Prior chemotherapy, immunotherapy/vaccine, hormonal or radiation therapy for melanoma","url":null,"context":"CTEP"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Has patient received prior treatment with a PI3K inhibitor?","url":null,"context":"PBTC"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-CTLA4, anti-CD137, anti-PD-L1 or anti-PD-1 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways?","url":null,"context":"PBTC"},{"name":"PBTC_Text3","type":"Alternate Question Text","description":"Patient has had prior HDAC, DAC, HSP90 inhibitors for the treatment of their DIPG?","url":null,"context":"PBTC"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Neoadjuvant therapy","url":null,"context":"Alliance"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Did the patient receive all planned therapy?","url":null,"context":"Alliance"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Neoadjuvant chemotherapy","url":null,"context":"Alliance"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Prior neoadjuvant therapy for this tumor","url":null,"context":"Alliance"},{"name":"PBTC_Text4","type":"Alternate Question Text","description":"Has the patient received prior treatment with CDK 4/6 inhibitors or mTOR inhibitors as described in the protocol?","url":null,"context":"PBTC"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Has the patient previously received a non FDA approved HDAC inhibitor in a clinical trial setting (e.g., entinostat, belinostat)","url":null,"context":"CTEP"},{"name":"CRF Text7","type":"Alternate Question Text","description":"Prior neoadjuvant systemic therapy for this tumor","url":null,"context":"Alliance"},{"name":"MA39","type":"Alternate Question Text","description":"Patient was treated with neoadjuvant chemo or endocrine therapy for breast cancer.","url":null,"context":"CCTG"},{"name":"PBTC_Text5","type":"Alternate Question Text","description":"Has patient received prior treatment with a MET inhibitor (e.g., foretinib, crizotinib, cabozantinib, or onartuzumab)?","url":null,"context":"PBTC"},{"name":"NRG CRF_Text 1","type":"Alternate Question Text","description":"Did the patient receive prior platinum-gemcitabine neoadjuvant (induction) therapy and/or adjuvant chemotherapy for primary non-metastatic/recurrent NPC more than 6 months prior to registration?","url":null,"context":"NRG"},{"name":"ALT_MA39_1","type":"Alternate Question Text","description":"Patient was treated with chemo or endocrine therapy administered in the neoadjuvant setting for breast cancer.","url":null,"context":"CCTG"},{"name":"PBTC_Text6","type":"Alternate Question Text","description":"Has patient received prior treatment with anti-CTLA4 , anti-CD137, anti-PD-L1 or anti-PD-1 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways? Exceptions to this criteria are agents considered to be CD40L Agonists","url":null,"context":"PBTC"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Has the patient had prior treatment with agent(s) targeting PI3K/AKT/mTor pathway?","url":null,"context":"NRG"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Patient has previously had induction or neo-adjuvant therapy.","url":null,"context":"CCTG"},{"name":"NRG CRF_Text 2","type":"Alternate Question Text","description":"Has the patient had prior treatment with an AKT inhibitor?","url":null,"context":"NRG"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Did neoadjuvant therapy consist of a minimum of 4 cycles (12 weeks) of chemotherapy in combination with HER2-targeted therapy?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B67A8C6B-CC80-05E3-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-12","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-02-12","modifiedBy":"TSESU","dateModified":"2022-11-21","changeDescription":"Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw","administrativeNotes":"2022.11.15 AQT added for ticket request CADSR0001687. ak","unresolvedIssues":null,"deletedIndicator":"No"}}